Literature DB >> 18469834

Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study.

G Assmann1, H Schulte, U Seedorf.   

Abstract

OBJECTIVES: We aimed (1) to construct a modified PROCAM risk algorithm, which incorporates BMI/waist circumference in a model for predicting coronary events; (2) to evaluate how accurate this and the previously established PROCAM risk algorithm predict coronary risk in individuals with metabolic syndrome.
DESIGN: Prospective Cardiovascular Münster (PROCAM) Study, a prospective study of men and women at work in the northwest of Germany.
SUBJECTS: A total of 7134 men aged 35-65 years at study entry. MEASUREMENTS: On the basis of 404 major coronary events (defined as nonfatal MI and coronary deaths), which occurred within 10 years of follow-up, a modified PROCAM risk algorithm was constructed by incorporating BMI/waist circumference as fixed variable in a Cox proportional hazards model for predicting coronary events. The metabolic syndrome was defined according to the latest recommendations proposed by the NCEP-ATP III Panel.
RESULTS: Men who were classified as having the metabolic syndrome (n=2325, prevalence: 32.6%) were 2.59-fold more likely to experience a major coronary event within 10 years of follow-up than men not having the metabolic syndrome. In men with metabolic syndrome, the observed major coronary event rate of 9.6% corresponded well with their estimated global risk according to the modified BMI-based PROCAM risk algorithm (10.2%). Comparative calculations performed with the previously published fully adjusted PROCAM algorithm yielded very similar results.
CONCLUSION: Both PROCAM algorithms provide very accurate means to ascertain coronary risk in male patients with metabolic syndrome.

Entities:  

Mesh:

Year:  2008        PMID: 18469834     DOI: 10.1038/ijo.2008.29

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  14 in total

Review 1.  Prediction models for risk classification in cardiovascular disease.

Authors:  Mario Petretta; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-03       Impact factor: 9.236

Review 2.  Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.

Authors:  Eoin P Judge; D Phelan; Donal O'Shea
Journal:  J R Soc Med       Date:  2010-09       Impact factor: 5.344

3.  Potential Linkage between High Normalized Electromechanical Activation Time (EMAT), an Early Systolic Time Interval Abnormality with Metabolic Syndrome.

Authors:  Kai-Hung Cheng; Jiun-Hung Geng; Cheng-Hsueh Lee; Chia-Chu Liu; Chao-Ping Wang; Shu-Pin Huang
Journal:  Acta Cardiol Sin       Date:  2021-11       Impact factor: 2.672

4.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

5.  'Functional' body composition: differentiating between benign and non-benign obesity.

Authors:  Manfred J Müller; Anja Bosy-Westphal; Martin Heller
Journal:  F1000 Biol Rep       Date:  2009-10-14

6.  Screening results for subclinical coronary artery calcification in asymptomatic individuals in relation to a detailed parental history of premature coronary heart disease.

Authors:  Stefanie Wahl; Stefan Möhlenkamp; Raimund Erbel; Susanne Moebus; Silke Andrich; Andreas Stang; Karl-Heinz Jöckel; Nico Dragano
Journal:  Eur J Epidemiol       Date:  2012-11-04       Impact factor: 8.082

7.  Metabolic syndrome, hormone levels, and inflammation in patients with erectile dysfunction.

Authors:  Miguel Ángel Arrabal-Polo; Salvador Arias-Santiago; Fernando López-Carmona Pintado; Sergio Merino-Salas; Clara Lahoz-García; Armando Zuluaga-Gómez; Miguel Arrabal-Martin
Journal:  ScientificWorldJournal       Date:  2012-09-02

8.  Is Early Onset Androgenic Alopecia a Marker of Metabolic Syndrome and Carotid Artery Atherosclerosis in Young Indian Male Patients?

Authors:  Harmeet Singh Banger; Suresh Kumar Malhotra; Sohan Singh; Mridula Mahajan
Journal:  Int J Trichology       Date:  2015 Oct-Dec

9.  Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  Russell Scott; Richard O'Brien; Greg Fulcher; Chris Pardy; Michael D'Emden; Dana Tse; Marja-Riitta Taskinen; Christian Ehnholm; Anthony Keech
Journal:  Diabetes Care       Date:  2008-11-04       Impact factor: 19.112

10.  The impact of estradiol and 1,25(OH)2D3 on metabolic syndrome in middle-aged Taiwanese males.

Authors:  Kai-Hung Cheng; Shu-Pin Huang; Chun-Nung Huang; Yung-Chin Lee; Chih-Sheng Chu; Chu-Fen Chang; Wen-Ter Lai; Chia-Chu Liu
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.